Sanegene Bio
Last verified 2026-06-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $118.0Mattributed |
|---|---|
| Latest round | series-b, $110.0M, 2025-12-01attributed |
| Founded | 2021 |
| Headquarters | Woburn, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | sanegenebio.com |
Sanegene Bio makes RNAi medicines for obesity, cardiometabolic, and autoimmune diseases using the LEAD system to direct gene-silencing payloads to liver, fat, muscle, and immune cells. Silencing disease genes across multiple tissue types from a single subcutaneous injection surpasses the liver-only targeting of earlier RNAi platforms.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-b | $110.0M | undisclosed |
Detected tech stack
unreachable
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $110.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $118.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | sanegenebio.com, read 2026-06-16 |
| Description | self-reported | sanegenebio.com, read 2026-06-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.